The stock of Arcutis Biotherapeutics Inc (ARQT) has gone down by -8.89% for the week, with a -5.00% drop in the past month and a 3.07% rise in the past quarter. The volatility ratio for the week is 6.04%, and the volatility levels for the past 30 days are 7.78% for ARQT. The simple moving average for the past 20 days is -3.39% for ARQT’s stock, with a 12.85% simple moving average for the past 200 days.
Is It Worth Investing in Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Right Now?
The 36-month beta value for ARQT is at 1.86. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ARQT is 104.90M, and currently, shorts hold a 13.71% of that float. The average trading volume for ARQT on May 07, 2025 was 2.52M shares.
ARQT) stock’s latest price update
Arcutis Biotherapeutics Inc (NASDAQ: ARQT)’s stock price has gone decline by -5.13 in comparison to its previous close of 14.32, however, the company has experienced a -8.89% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-05-07 that Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a monotherapy 66.4% of individuals treated with ZORYVE foam achieved Scalp-Investigator Global Assessment (S-IGA) Success at Week 8 45.5% of individuals treated with ZORYVE foam achieved Body-Investigator Global Assessment (B-IGA) Success at Week 8 Efficacy and safety results were consistent with Phase 2 results of ZORYVE foam 0.3% in adults and adolescents 12 years of age and older Supplemental New Drug Application (sNDA) for investigational ZORYVE foam 0.3% for psoriasis is under review with U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) action date of May 22, 2025 More than half of the nearly 9 million people in the United States with plaque psoriasis experience scalp involvement WESTLAKE VILLAGE, Calif., May 07, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Journal of American Medical Association (JAMA) Dermatology published the positive results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE® (roflumilast) foam 0.3% as a once-daily monotherapy treatment for psoriasis of the scalp and body.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with H.C. Wainwright repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to H.C. Wainwright is $19 based on the research report published on December 30, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $15. The rating they have provided for ARQT stocks is “Buy” according to the report published on August 28th, 2024.
Mizuho gave a rating of “Buy” to ARQT, setting the target price at $8 in the report published on January 03rd of the previous year.
ARQT Trading at -7.80% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.46% of loss for the given period.
Volatility was left at 7.78%, however, over the last 30 days, the volatility rate increased by 6.04%, as shares surge +2.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.05% upper at present.
During the last 5 trading sessions, ARQT fell by -8.32%, which changed the moving average for the period of 200-days by +40.21% in comparison to the 20-day moving average, which settled at $14.07. In addition, Arcutis Biotherapeutics Inc saw -2.48% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Matsuda Masaru, who sale 5,030 shares at the price of $15.20 back on May 02 ’25. After this action, Matsuda Masaru now owns 204,399 shares of Arcutis Biotherapeutics Inc, valued at $76,453 using the latest closing price.
Watanabe Todd Franklin, the of Arcutis Biotherapeutics Inc, sale 11,448 shares at $15.19 during a trade that took place back on May 02 ’25, which means that Watanabe Todd Franklin is holding 913,795 shares at $173,917 based on the most recent closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -0.65 for the present operating margin
- 0.9 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -0.71. The total capital return value is set at -0.48. Equity return is now at value -113.76, with -40.58 for asset returns.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at -1.01. The debt to equity ratio resting at 0.7. The interest coverage ratio of the stock is -4.73.
Currently, EBITDA for the company is -109.62 million with net debt to EBITDA at -0.36. When we switch over and look at the enterprise to sales, we see a ratio of 8.56. The receivables turnover for the company is 2.69for trailing twelve months and the total asset turnover is 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.15.
Conclusion
In conclusion, Arcutis Biotherapeutics Inc (ARQT) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
